RESEARCH DIGEST · QUESTIONS
CJC-1295 Questions, Answered From the Record
The definitional, dosing, safety, and regulatory questions people actually ask about CJC-1295 — each answered directly, in research context, and cited where it makes a quantitative claim.
Definitional
What is CJC-1295?
CJC-1295 is a synthetic long-acting analog of growth-hormone-releasing hormone (GHRH), built on the hGRF(1-29) fragment with four protease-resistant substitutions; the DAC variant adds covalent serum-albumin conjugation for a multi-day half-life [1][2].
What does CJC-1295 do?
In studies it binds the pituitary GHRH receptor, stimulating pulsatile growth-hormone release that in turn raises hepatic IGF-1; a single dose elevated GH and IGF-1 for days in early human pharmacokinetic work [1][3].
Is CJC-1295 a steroid?
No. CJC-1295 is a peptide GHRH analog — a growth-hormone secretagogue — not an anabolic-androgenic steroid; it acts upstream on the GH/IGF-1 axis rather than on androgen receptors.
What is CJC-1295 / ipamorelin?
A research pairing of a GHRH analog (CJC-1295) with a selective GH secretagogue (ipamorelin); the two act through distinct receptors, which is the mechanistic basis cited for combining a GHRH analog with a GHRP.
What is CJC-1295 with DAC?
The Drug Affinity Complex variant adds a maleimide linker that covalently binds the peptide to serum albumin at cysteine-34, extending the plasma half-life toward that of albumin itself and giving a multi-day duration [2].
What is CJC-1295 DAC?
CJC-1295 DAC is the long-acting form: the tetrasubstituted GHRH(1-29) sequence plus the albumin-binding DAC moiety, distinct from the short-acting no-DAC 'Modified GRF 1-29' [1][2].
Dosing and Handling
How much CJC-1295 should I take?
There is no established human dose. Published human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 µg/kg [1][3]; circulating fixed-dose 'protocols' are not derived from controlled human trials. Described for research context only.
How much CJC-1295 DAC should I take?
No validated human dose exists for the DAC form. Its multi-day half-life — estimated at 5.8 to 8.1 days [1] — underlies why community schedules are spaced out, but those schedules are not from controlled human efficacy trials.
How much CJC-1295 / ipamorelin should I take?
No controlled human trial defines a CJC-1295/ipamorelin dose. Community 'protocols' commonly cite fixed microgram doses, but these are not trial-derived; the literature establishes the two-receptor synergy rationale, not a regimen [1].
How to reconstitute CJC-1295?
As a lyophilized peptide it is reconstituted with bacteriostatic water and refrigerated; oral bioavailability is negligible. Described as laboratory handling, not human-use instructions.
Where to inject CJC-1295?
Subcutaneous injection was the primary route in CJC-1295 studies (early GRF(1-29) work also used intravenous) [1][3]. Stated as the route used in the research, not as administration guidance.
Safety
Is CJC-1295 safe?
CJC-1295 is an unapproved research chemical with only limited early human data; theoretical concerns include sustained IGF-1 elevation (epidemiologically linked to some cancer risk), fluid retention, and FDA-cited immunogenicity [1]. No safety claim can be made for human use.
Are CJC-1295 peptides safe?
Published human safety data are limited to early pharmacokinetic studies [1][3]; CJC-1295 is unapproved, and theoretical risks (IGF-1/cancer epidemiology, fluid retention, immunogenicity) mean no safety assurance can be offered for human use.
Does CJC affect testosterone?
CJC-1295 acts on the GH/IGF-1 axis, not the gonadal axis; it is not a testosterone-raising or testosterone-lowering agent. Some GH-secretagogue research in specific populations measured IGF-1, not testosterone, as the readout.
What are the side effects of CJC-1295?
Reported and theoretical concerns include fluid retention and edema (GH stimulates renal sodium reabsorption), effects on insulin sensitivity, sustained IGF-1 elevation [1], and FDA-cited immunogenicity; the controlled human safety record is thin.
Does CJC-1295 lower testosterone?
There is no established mechanism by which CJC-1295 lowers testosterone; it stimulates the GH/IGF-1 axis upstream of the pituitary's somatotrophs, separate from gonadotropin signaling [1].
Does CJC-1295 raise testosterone?
CJC-1295 targets the GH/IGF-1 axis, not androgen production; it is not characterized in the literature as a testosterone-raising agent.
Are peptides safer than TRT?
This cannot be concluded for CJC-1295: unlike an FDA-approved GHRH analog such as tesamorelin, CJC-1295 has no approved indication and only limited human data, so no safety comparison to established hormone therapy is supportable [12].
What are the potential side effects or risks of using peptides such as CJC-1295 to build muscle mass?
Risks discussed in the literature for GH-axis stimulation include fluid retention, insulin-sensitivity effects, and the IGF-1/cancer-risk epidemiology; the muscle-building case rests largely on IGF-1 signaling theory, not on controlled human outcome trials of CJC-1295 [1].
Efficacy, Expectations, and Regulatory Status
Does CJC-1295 and ipamorelin work?
GHRH analogs and GHRPs synergize to release more GH together than either alone, and CJC-1295 alone raised GH and IGF-1 in early human pharmacokinetic studies [1][3]; however, no controlled efficacy trial of the combination in healthy adults exists.
What to expect when taking CJC-1295?
Early human pharmacokinetic studies described dose-dependent rises in GH and IGF-1 lasting days, with GH pulsatility preserved [1][3]; this is study data, not a description of effects to expect from non-clinical use.
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved for human use by the FDA or any major regulator; it is handled as a research chemical, and the 2024 FDA Pharmacy Compounding Advisory Committee did not recommend it for the 503A compounding bulks list. CJC-1295 is also prohibited at all times in sport under WADA Section S2.